ArticleCureus2024
Primary Laryngeal Lymphoma: A Case Report of a Rare Entity.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary laryngeal lymphoma is a rare form of non-Hodgkin lymphoma (NHL), with fewer than 100 cases reported worldwide. Although head and neck cancers are the second most common extranodal sites for NHL, the larynx, particularly the supraglottic region, is rarely involved. We present a case that underscores the importance of distinguishing primary laryngeal lymphoma from secondary involvement to ensure the appropriate management of the condition. A 53-year-old male presented with significant weight loss, hoarseness, and progressive dysphagia. He also reported an intermittent history of fever and night sweats. Physical examination revealed bilateral level IIa and III cervical lymphadenopathy and flexible laryngoscopy showed edema and ulceration in the supraglottic region. A contrast-enhanced CT scan from the skull base to the thorax revealed a fairly well-defined, mildly heterogeneous enhancing lesion involving the suprahyoid and glottic regions, measuring 2.3 x 2.1 x 5 cm (AP x TR x CC). Biopsy confirmed diffuse large B-cell lymphoma (DLBCL), with immunohistochemistry positive for CD45, CD20, and BCL6. The patient received eight cycles of the CHOP (doxorubicin, cyclophosphamide, prednisone, and vincristine) chemotherapy regimen, achieving complete clinical remission with no recurrence noted at the two-year follow-up. DLBCL of the larynx is rare but should be considered in cases of supraglottic masses due to its symptom overlap with other laryngeal conditions. Diagnosis is confirmed through histopathology and immunohistochemistry, and treatment typically involves chemotherapy, with CHOP being the most effective regimen. Early recognition is crucial for optimal treatment of this uncommon disease. Further research is needed to refine treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.